Combination of localized scleroderma with other autoimmune skin diseases: clinical and pathogenetic aspects

Capa

Citar

Texto integral

Acesso aberto Acesso aberto
Acesso é fechado Acesso está concedido
Acesso é fechado Somente assinantes

Resumo

The article provides a comprehensive analysis of modern data on the clinical and pathogenetic features of comorbid forms of localized scleroderma, including a review of literature sources and a description of our own clinical observations. The results obtained expand the understanding of the pathogenesis of autoimmune dermatoses and may contribute to the improvement of diagnostic and therapeutic algorithms for the management of patients with combined pathology.

Sobre autores

M. Abo Khadeejeh

Peoples’ Friendship University of Russia named after Patrice Lumumba

Autor responsável pela correspondência
Email: marykor@bk.ru
ORCID ID: 0000-0003-0837-822X
Rússia, Moscow

Z. Niewozinska

Moscow Research and Practical Center of Dermatovenereology and Cosmetology, Moscow Healthcare Department

Email: marykor@bk.ru
ORCID ID: 0000-0002-5913-9635
Código SPIN: 5572-5750

Candidate of Medical Sciences

Rússia, Moscow

E. Radionova

Moscow Research and Practical Center of Dermatovenereology and Cosmetology, Moscow Healthcare Department

Email: marykor@bk.ru
ORCID ID: 0000-0002-2642-9126

Candidate of Medical Sciences

Rússia, Moscow

E. Denisova

Moscow Research and Practical Center of Dermatovenereology and Cosmetology, Moscow Healthcare Department; Center for Theoretical Problems of Physicochemical Pharmacology, Russian Academy of Sciences

Email: marykor@bk.ru
ORCID ID: 0000-0002-4887-284X
Código SPIN: 3570-5779

Candidate of Medical Sciences

Rússia, Moscow; Moscow

O. Zhukova

Peoples’ Friendship University of Russia named after Patrice Lumumba; Moscow Research and Practical Center of Dermatovenereology and Cosmetology, Moscow Healthcare Department

Email: marykor@bk.ru
ORCID ID: 0000-0001-5723-6573
Código SPIN: 8584-7564

MD, Professor

Rússia, Moscow; Moscow

I. Korsunskaya

Center for Theoretical Problems of Physicochemical Pharmacology, Russian Academy of Sciences

Email: marykor@bk.ru
ORCID ID: 0000-0002-6583-0318
Código SPIN: 3335-2019

MD, Professor

Rússia, Moscow

Bibliografia

  1. Distler O., Cozzio A. Systemic sclerosis and localized scleroderma: current concepts and novel targets for therapy. Semin Immunopathol. 2016; 38 (1): 87–95. doi: 10.1007/s00281-015-0551-z
  2. Потекаев Н.Н., Васенова В.Ю., Полеско И.В. и др. Буллезная форма склеродермии: опыт комбинированной терапии. Клиническая дерматология и венерология. 2024; 23 (1): 45–8 [Potekaev N.N., Vasenova V.Yu., Polesko I.V. et al. Bullous scleroderma: experience of combined therapy. Russian Journal of Clinical Dermatology and Venereology. 2024; 23 (1): 45–8 (in Russ.)]. doi: 10.17116/klinderma20242301145
  3. Kortelainen S., Hieta N., Rissanen T. et al. Localized scleroderma and related comorbidities: a single centre cohort study. Br J Dermatol. 2025; ljaf419. doi: 10.1093/bjd/ljaf41
  4. Lubrano E., Delle Sedie A., Romanelli M. et al. Management of psoriatic arthritis in rheumatology and dermatology settings: sub-analysis of the Italian population from the international LOOP study. Clin Rheumatol. 2021; 40 (6): 2251–62. doi: 10.1007/s10067-020-05482-w
  5. Elhai M., Meune C., Avouac J. et al. Trends in mortality in patients with systemic sclerosis over 40 years: a systematic review and meta-analysis of cohort studies. Rheumatology (Oxford). 2012; 51 (6): 1017–26. doi: 10.1093/rheumatology/ker269
  6. Fett N., Werth V.P. Update on morphea: part I. Epidemiology, clinical presentation, and pathogenesis. J Am Acad Dermatol. 2011; 64 (2): 217–8; quiz 229-30. doi: 10.1016/j.jaad.2010.05.045
  7. Knobler R., Geroldinger-Simic M., Kreuter A. et al. European guidelines for the diagnosis and treatment of localized scleroderma. J Eur Acad Dermatol Venereol. 2022; 36 (6): 791–809. doi: 10.1111/jdv.17952
  8. Torok K.S., Li S.C., Jacobe H.M. et al. Immunopathogenesis of pediatric localized scleroderma. Front Immunol. 2019; 10: 908. doi: 10.3389/fimmu.2019.00908
  9. Zhou X., Tan F.K., Xiong M. et al. Systemic sclerosis (scleroderma): specific autoantigen genes are selectively overexpressed in scleroderma fibroblasts. J Immunol. 2001; 167 (12): 7126–33. doi: 10.4049/jimmunol.167.12.7126
  10. Leitenberger J.J., Cayce R.L., Haley R.W. et al. Distinct autoimmune syndromes in morphea: a review of 245 adult and pediatric cases. Arch Dermatol. 2009; 145 (5): 545–50. doi: 10.1001/archdermatol.2009.79
  11. Lis-Święty A., Janicka I., Skrzypek-Salamon A. et al. Localized scleroderma: clinical and epidemiological features with emphasis on adulthood- versus childhood-onset disease differences. J Eur Acad Dermatol Venereol. 2017; 31 (10): 1595–603. doi: 10.1111/jdv.14197
  12. Zulian F., Vallongo C., Woo P. et al. Localized scleroderma in childhood is not just a skin disease. Arthritis Rheum. 2005; 52 (9): 2873–81. doi: 10.1002/art.21264
  13. Peterson L.S., Nelson A.M., Su W.P. et al. The epidemiology of morphea (localized scleroderma) in Olmsted County 1960–1993. J Rheumatol. 1997; 24 (1): 73–80.
  14. Мурашкин Н.Н., Савелова А.А., Иванов Р.А. и др. Вопросы этиопатогенетической общности сочетанных форм локализованной склеродермии и витилиго. Вопросы современной педиатрии. 2020; 19 (6): 452–9 [Murashkin N.N., Savelova A.A., Ivanov R.A. et al. Etiopathogenetic Similarities of Combined Forms of Localized Scleroderma and Vitiligo. Current Pediatrics. 2020; 19 (6): 452–9 (in Russ.)]. doi: 10.15690/vsp.v19i6.2147
  15. Krasowska D., Rudnicka L., Dańczak-Pazdrowska A. et al. Localized scleroderma (morphea). Diagnostic and therapeutic recommendations of the Polish Dermatological Society. Dermatol Rev. 2019; 106: 333–53. doi: 10.5114/dr.2019.88252
  16. Mir A., Tlougan B., O'Reilly K. et al. Morphea with discoid lupus erythematosus. Dermatol Online J. 2011; 17 (10): 10.
  17. Sener S., Batu E.D. Use of biologic drug in the treatment of localized scleroderma and systemic sclerosis in children: A scoping review. Semin Arthritis Rheum. 2025; 71: 152634. doi: 10.1016/j.semarthrit.2025.152634
  18. Gumkowska-Sroka O., Kotyla K., Mojs E. et al. Novel Therapeutic Strategies in the Treatment of Systemic Sclerosis. Pharmaceuticals (Basel). 2023; 16 (8): 1066. doi: 10.3390/ph16081066
  19. Hudson M., Thombs B.D., Steele R. et al. Quality of life in patients with systemic sclerosis compared to the general population and patients with other chronic conditions. J Rheumatol. 2009; 36 (4): 768–72. doi: 10.3899/jrheum.080281
  20. Dańczak-Pazdrowska Al., Kowalczyk M., Szramka-Pawlak B. et al. Interleukin-17A and interleukin-23 in morphea. Arch Med Sci. 2012; 8 (6): 1089–95. doi: 10.5114/aoms.2012.32421
  21. Kunz M., König I.R., Schillert A. et al. Genome-wide association study identifies new susceptibility loci for cutaneous lupus erythematosus. Exp Dermatol. 2015; 24 (7): 510–5. doi: 10.1111/exd.12708
  22. Dahir A.M., Thomsen S.F. Comorbidities in vitiligo: comprehensive review. Int J Dermatol. 2018; 57 (10): 1157–64. doi: 10.1111/ijd.14055
  23. Richmond J.M., Bangari D.S., Essien K.I. Keratinocyte-Derived Chemokines Orchestrate T-Cell Positioning in the Epidermis during Vitiligo and May Serve as Biomarkers of Disease. J Invest Dermatol. 2017; 137 (2): 350–8. doi: 10.1016/j.jid.2016.09.016
  24. Richmond J.M., Frisoli M.L., Harris J.E. Innate immune mechanisms in vitiligo: danger from within. Curr Opin Immunol. 2013; 25 (6): 676–82. doi: 10.1016/j.coi.2013.10.010
  25. Kahle J., Rohr B., Shah S.D. The co-occurrence of segmental vitiligo and linear morphea in a pediatric patient and a review of the literature. Pediatr Dermatol. 2023; 40 (3): 507–10. doi: 10.1111/pde.15180
  26. Потекаев Н.Н., Корсунская И.М., Гусева С.Д. и др. Склеродермия: общий взгляд на проблему. Клиническая дерматология и венерология. 2013; 11 (5): 6–10 [Potekaev N.N., Korsunskaia I.M., Guseva S.D. et al. Scleroderma: a general view of the problem. Russian Journal of Clinical Dermatology and Venereology. 2013; 11 (5): 6–10 (in Russ.)].
  27. Connelly M.G., Winkelmann R.K. Coexistence of lichen sclerosus, morphea, and lichen planus. Report of four cases and review of the literature. J Am Acad Dermatol. 1985; 12 (5 Pt 1): 844–51. doi: 10.1016/s0190-9622(85)70106-5
  28. Melato M., Gorji N., Rizzardi C. et al. Associated localization of morphea and lichen planus of the lip in a patient with vitiligo. Minerva Stomatol. 2000; 49 (11-12): 549–54.
  29. Shidahara K., Hayashi K., Sada K.E. et al. Refractory neuromyelitis optica spectrum disorder in systemic lupus erythematosus successfully treated with rituximab. Lupus. 2018; 27 (8): 1374–7. doi: 10.1177/0961203318760994
  30. Tolkachjov S.N., Chaudhry H.M., Camilleri M.J. et al. Frontal fibrosing alopecia among men: A clinicopathologic study of 7 cases. J Am Acad Dermatol. 2017; 77 (4): 683–90.e2. doi: 10.1016/j.jaad.2017.05.045
  31. Simpson E.L. Comorbidity in Atopic Dermatitis. Curr Dermatol Rep. 2012; 1 (1): 29–38. doi: 10.1007/s13671-011-0003-5

Arquivos suplementares

Arquivos suplementares
Ação
1. JATS XML
Baixar

Согласие на обработку персональных данных

 

Используя сайт https://journals.rcsi.science, я (далее – «Пользователь» или «Субъект персональных данных») даю согласие на обработку персональных данных на этом сайте (текст Согласия) и на обработку персональных данных с помощью сервиса «Яндекс.Метрика» (текст Согласия).